The chief scientific officer of CureDuchenne discussed challenges to tackle in the field.
Michael Kelly, PhD
Advertisement
Articles by Michael Kelly, PhD
The chief scientific officer of CureDuchenne discussed how nonviral approaches may address issues including gene size and redosability.
The chief scientific officer of CureDuchenne discussed research he is looking forward to seeing in 2024.
The chief scientific officer of CureDuchenne discussed progress in the field so far and upcoming milestones.
Advertisement
Latest Updated Articles
Uptake of Nononcology Gene Therapy Remains Slow in HematologyPublished: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLDPublished: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 DataPublished: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell TherapyPublished: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMDPublished: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of VisionPublished: May 18th 2023 | Updated:
Advertisement
Advertisement
